Dr Matteo Lambertini speaks to ecancer at ASCO 2024 about an international cohort study evaluating the clinical behaviour of breast cancer in young BRCA carriers and prognostic impact of the timing of genetic testing.

He explains that data was collected from 4752 patients across 26 countries and 78 centres.

Dr Lambertini reports that BRCA1 and BRCA2 carriers had developed tumours with different characteristics and different clinical behaviour.

On top of this, healthy individuals carrying a BRCA pathogenic variant had earlier breast cancer diagnosis and improved overall survival.